Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

JPMorgan upgraded Recursion Pharmaceuticals (RXRX) to Overweight from Neutral with a price target of $11, up from $10. The firm says the company’s REC-4881 has shown “strong and durable” efficacy in ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, Recursion announced positive Phase 1b/2 results for REC-4881, which is its ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Machine learning is reshaping the way portfolios are built, monitored, and adjusted. Investors are no longer limited to ...

Cathie Wood’s ARK ETF published their daily trades for Friday, December 19th, 2025, showcasing significant activity in several key stocks. Leading the trades was a substantial sale of 23,110 shares of ...

Condé Nast Traveler readers believe this major US city is the end-all-be-all for shopping destinations in the country.

昨日大涨11.4%的Recursion(RXRX.US)盘前续涨3.8%。消息上，摩根大通将Recursion Pharmaceuticals的评级由“中性”上调至“增持”，理由是 ...

Introduction Application of artificial intelligence (AI) tools in the healthcare setting gains importance especially in the domain of disease diagnosis. Numerous studies have tried to explore AI in ...